To appraise the clinical and cost effectiveness of TYRX within its CE mark for preventing infection from cardiac implantable electronic devices.
 
Status In progress
Process STA 2018
ID number 1440

Provisional Schedule

Committee meeting: 1 26 November 2019
Expected publication 19 February 2020

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Consultees

Companies sponsors Medtronic (TYRX Absorbable Antibacterial Envelope)
Others Department of Health and Social Care
  NHS England
  NHS Leicester City CCG
  NHS Newham CCG
  Welsh Government
Patient carer groups Arrhythmia Alliance
  Atrial Fibrillation Association
  British Cardiac Patients Association
  British Heart Foundation
  Blood Pressure UK
  Cardiac Risk in Young Children
  Cardiomyopathy UK
  Cardiovascular Care Partnership
  HEART UK
  Muslim Council of Britain
  Pumping Marvellous Foundation
  Royal College of Surgeons Patient Liaison Group
  The Ashley Jolly SADS UK Trust
  The Sepsis Trust
  Somerville Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  UK Health Forum
Professional groups Association of Anaesthetists
  Association of Surgeons of Great Britain and Ireland
  British Association for Nursing in Cardiovascular Care
  British Cardiovascular Society
  British Geriatrics Society
  British Heart Foundation
  British Heart Rhythm Society
  British Nuclear Cardiology Society
  The British Society for Heart Failure
  Royal College of Emergency Medicine
  Royal College of General Practitioners
  Royal College of Anaesthetists
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons of England
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Cardiological Science and Technology
  Society for Cardiothoracic Surgery in Great Britain and Ireland
  UK Health Forum
  Society of Cardiothoracic Surgeons
  UK Clinical Pharmacy Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord UK (vancomycin)
  Flynn Pharma (vancomycin)
  Sanofi (gentamicin, teicoplanin)
  Syntacoll GmbH (Collatamp G)
  Wockhardt UK (flucloxacillin, gentamicin, vancomycin)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Association of British Healthcare Industries
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  EUCOMED
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  NHS Supply Chain
  Royal College of Physicians of Edinburgh
  Royal College of Surgeons of Edinburgh
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Society for Cardiovascular Research
  Cardiac and Cardiology Research Dept, Barts
  Cochrane Heart Group
  National Centre for Cardiovascular Preventions and Outcomes
  Heart Research UK
  MRC Clinical Trials Unit
  National Institute for Health Research
  Wellcome Trust

Timeline

Key events during the development of the guidance:

Date Update
29 March 2019 Invitation to participate
29 March 2019 In progress, The invitation to participate went out to the stakeholders.
13 September 2018 (10:00) Scoping workshop (London)
23 July 2018 - 20 August 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance